GH Research PLC will host a conference call on February 3, 2025, to discuss Phase 2b trial data for GH001.
Quiver AI Summary
GH Research PLC announced that it will hold a conference call and live webcast on February 3, 2025, at 8:00 a.m. EST to provide updates on the Phase 2b trial of its product candidate GH001 for treatment-resistant depression (TRD). The trial is a randomized, double-blind, placebo-controlled study. GH001, which utilizes a proprietary inhalation method for mebufotenin administration, showed promising results in a previous trial, with 87.5% of TRD patients achieving ultra-rapid remission. Interested parties can register for the call in advance, and the webcast will be accessible from the company's website under the Investors section.
Potential Positives
- GH Research PLC is hosting a conference call and live webcast to provide important updates on the Phase 2b trial of its lead product candidate, GH001, indicating transparency and ongoing communication with investors.
- The Phase 2 trial data for GH001 shows promising results, with 87.5% of patients achieving ultra-rapid remission from treatment-resistant depression, suggesting a significant advancement in treatment options.
- GH001 utilizes a proprietary inhalation approach, which could position the company as a leader in innovative treatment methods for psychiatric disorders.
Potential Negatives
- Data from the Phase 2b trial of GH001 may not yield the expected positive results, creating uncertainty around the product's efficacy for treatment-resistant depression.
- The need for a live webcast and conference call to update investors may indicate that prior communication regarding GH001's development was insufficient or raised concerns.
- As a clinical-stage company, any adverse outcomes from the upcoming trial could significantly impact investor confidence and the company's market position.
FAQ
What is the focus of GH Research PLC?
GH Research PLC focuses on transforming treatments for psychiatric and neurological disorders, particularly through innovative therapies for treatment-resistant depression.
When is the GH Research PLC conference call?
The conference call is scheduled for Monday, February 3, 2025, at 8:00 a.m. EST.
How can I access the conference call and webcast?
You can register for the conference call in advance and the live webcast will be available on GH Research's website under “Events & Presentations.”
What is GH001 and its significance?
GH001 is GH Research's lead product candidate for treatment-resistant depression, showing significant efficacy in clinical trials for rapid remission.
What were the results of the Phase 1/2 trial for GH001?
In the Phase 1/2 trial, 87.5% of patients achieved ultra-rapid remission using GH001's individualized single-day dosing regimen.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$GHRS Hedge Fund Activity
We have seen 10 institutional investors add shares of $GHRS stock to their portfolio, and 11 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- LYNX1 CAPITAL MANAGEMENT LP added 229,168 shares (+5.8%) to their portfolio in Q3 2024, for an estimated $1,533,133
- FMR LLC removed 220,929 shares (-7.4%) from their portfolio in Q3 2024, for an estimated $1,478,015
- RA CAPITAL MANAGEMENT, L.P. added 85,000 shares (+1.3%) to their portfolio in Q3 2024, for an estimated $568,650
- VERITION FUND MANAGEMENT LLC removed 82,850 shares (-7.3%) from their portfolio in Q3 2024, for an estimated $554,266
- CITADEL ADVISORS LLC added 58,225 shares (+37.0%) to their portfolio in Q3 2024, for an estimated $389,525
- WOODLINE PARTNERS LP added 37,238 shares (+inf%) to their portfolio in Q3 2024, for an estimated $249,122
- MORGAN STANLEY removed 33,325 shares (-11.4%) from their portfolio in Q3 2024, for an estimated $222,944
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
DUBLIN, Jan. 31, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced that it will host a conference call and live webcast on Monday, February 3, 2025, at 8.00 a.m. EST to provide an update on data from the randomized, double-blind, placebo-controlled Phase 2b trial of GH001 in treatment-resistant depression (TRD).
To access the conference call, please register in advance here . A live webcast of the call will be available under “Events & Presentations” in the Investors section of GH Research PLC’s website at ghres.com.
About GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary mebufotenin therapies for the treatment of patients with treatment-resistant depression (TRD).
About GH001
Our lead product candidate, GH001, is formulated for mebufotenin administration via a proprietary inhalation approach. Based on the observed clinical activity in our completed phase 1/2 GH001-TRD-102 trial, where 87.5% of patients with TRD achieved ultra-rapid remission with our GH001 individualized single-day dosing regimen in the Phase 2 part of the trial, we believe that GH001 has the potential to change the way TRD is treated today.
Investor Relations
Julie Ryan
GH Research PLC
[email protected]
